Table 2 Incidence of thromboembolic events with aromatase inhibitors and comparators
From: The effects of aromatase inhibitors on lipids and thrombosis
Thromboembolic events (% of patients) | |||
|---|---|---|---|
Reference | Aromatase inhibitor | Comparator | P -value |
Anastrozole 64 (2.1%) | Tamoxifen 109 (3.5%) | =0.0006 | |
Coombes et al (2004) (IES Trial) | Exemestane 30 (1.3%) | Tamoxifen 55 (2.4%) | =0.007 |
Letrozole (2.5 mg) 1 (0%) | Megestrol acetate 15 (7.9%) | Unknown | |
Letrozole (0.5 mg) 2 (1%) | |||
Goss et al (2003) (MA-17 trial) (cardiovascular events) | Letrozole (2.5 mg) 88 (4.1%) | Placebo 77 (3.6%) | =0.4 |
